Background {#Sec1}
==========

Myeloid sarcoma (MS), a solid tumor consisting of myeloid blasts or immature myeloid cells outside the bone marrow, is an unusual presentation of acute myeloid leukemia (AML). MS is also known by other names---e.g., chloroma, granulocytic sarcoma---which can create some confusion in understanding this disease. MS can develop anywhere in the body, with the most common sites being the lymph nodes, bone/spine, and skin. Development of MS in the small intestine is reported to account for 10--11% of all MSs occurring in the gastrointestinal tract \[[@CR1]\]. Because of its rarity and difficult diagnosis, MS has often been misdiagnosed as other diseases \[[@CR2]\]. Here, we report a rare case of isolated primary MS of the small bowel causing intestinal obstruction.

Case presentation {#Sec2}
=================

A 54-year-old man with a history of hypertension and hyperlipidemia was admitted to our hospital complaining of abdominal pain and vomiting. He showed abdominal bloating but no signs of peritoneal irritation. Contrast-enhanced computed tomography (CT) revealed local thickening of the small bowel wall, which was assumed to be due to an inflammatory reaction (Fig. [1](#Fig1){ref-type="fig"}). We diagnosed inflammatory disease, administered conservative treatment, which was effective, and did not perform further checkups. After resuming oral intake, he was discharged 10 days after admission. A few days after discharge, however, his abdominal symptoms recurred, and he was readmitted to our hospital. Fig. 1Contrast-enhanced abdominal computed tomography shows thickening of the small bowel wall. **a** Axial view. **b** Coronal view

Blood tests showed a mild inflammatory reaction and dehydration. The white blood cell count was 8200/μl, with 62.3% neutrophils, 28.3% lymphocytes, 0.7% eosinophils, 0.5% basophils, and 8.3% monocytes. Other laboratory tests showed the following: hemoglobin 14.5 g/dl, platelets 265,000/μl, CEA 7.5 ng/ml, CA19-9 4.5 U/ml, and sIL-2R 313 U/ml. After insertion of an ileus tube, a small bowel series revealed severe obstruction in the jejunum with upstream dilatation (Fig. [2](#Fig2){ref-type="fig"}). CT showed that thickening of the jejunal wall was still causing obstruction. Because of the results of those assessments, we performed a laparoscopic exploratory examination for a more accurate diagnosis. The laparoscopic views revealed a hard mass at the stenotic site, prompting us to perform small bowel resection with mesenteric lymph node dissection in consideration that the tumor might be malignant. The surgical view showed a palpable, elastic, hard mass in the jejunum, necessitating partial resection of the jejunum with 10-cm margins from the tumor on both sides and mesenteric lymphadenectomy. During the lymph node dissection of the small intestinal mesentery, we removed seven lymph nodes, none of which showed signs of metastasis. Fig. 2Small bowel series via the ileus tube shows severe obstruction in the jejunum with upstream dilatation

Macroscopic examination of the resected specimen revealed a tumor approximately 60 mm in diameter that had caused stenosis of the entire jejunal circumference (Fig. [3](#Fig3){ref-type="fig"}). Histologically, hematoxylin and eosin (HE) staining showed diffuse infiltration and expansion of immature, atypical cells but without tissue destruction (Fig. [4](#Fig4){ref-type="fig"}). Immunochemical staining revealed that the cells were positive for myeloperoxidase (MPO) and CD34 and negative for CD20 (L26), CD3, CD30 (Ki1), CK (AE1/AE3), CK (MNF116), desmin, CD56, HMB-45, and S-100-protein (Fig. [5](#Fig5){ref-type="fig"}). These results confirmed the diagnosis of isolated jejunal MS. The patient's postoperative recovery was uneventful, and he was discharged from the hospital 9 days after the surgery. Fig. 3Resected mass measured approximately 60 × 50 mm. The mass, which was elastic and hard, blocked the entire circumference of the elevated cut surface Fig. 4Small intestine specimen shows diffuse infiltration and expansion of immature, atypical cells without tissue destruction (HE; **a** × 20, **b** × 200) Fig. 5Immunohistochemistry shows staining of the tumor cells for myeloperoxidase (MPO) (**a**) and CD34 (**b**)

Although the bone marrow aspiration evaluation was negative for cytological findings of leukemia, and ^18^F-fluorodeoxyglucose-positron emission tomography (FDG-PET) showed no abnormal uptake, the patient was started on systemic chemotherapy for AML 6 months after his surgery.

Discussion {#Sec3}
==========

MS occurs as an initial or replacement presentation of AML and sometimes as a complication of myeloproliferative disorders. Isolated MS is rare, with only 1.4--9.0% of AML patients reported to develop MS \[[@CR3]\]. Kitagawa et al. reported that the interval between the diagnosis of MS and the occurrence of AML varied from 0.5 to 24 months in patients with initial MS \[[@CR2]\]. The male/female ratio is 1.2:1, and the median age was 56 years (range 1 month to 89 years) \[[@CR4]\].

Imaging and biopsy results are useful for confirming the diagnosis. FDG-PET shows high uptake by the tumor, and pathological examination shows both diffuse and concentrated areas of hyperplasia with large oval cells \[[@CR1], [@CR5]\]. It has been reported, however, that almost half the patients with MS have been misdiagnosed as having a primary or metastatic malignant tumor, especially malignant lymphoma \[[@CR2], [@CR6]\]. We did not list MS in the differential diagnosis of the patient and thus arrived at a misdiagnosis. Immunohistochemical examinations (e.g., CD68/KP1, CD33, CD34, CD117, and MPO) are performed to characterize the MS \[[@CR4]\]. In our case, MPO was useful for establishing an accurate diagnosis.

Surgical resection is performed to treat an intestinal obstruction, as in our case, but MS patients should be treated with systemic chemotherapy tailored to the AML. Yamauchi and Yasuda analyzed 74 clinical records and showed that the median interval from MS to acute non-lymphocytic leukemia was significantly shorter among the patients who underwent surgical resection with or without irradiation than in those treated with chemotherapy only \[[@CR6]\].

MS is rarely seen in the small intestine and certainly would not be easily recognized by general surgeons. Moreover, there is some confusion about the terminology. MS is described as a granulocytic sarcoma (extramedullary myelogenous leukemia) in *Diagnostic Surgical Pathology, 3rd Edition* published in 1999 and as a granulocytic sarcoma or a chloroma in *Surgical Pathology, 10th Edition* published in 2011 \[[@CR7], [@CR8]\]. Furthermore, it is called a myeloid sarcoma, granulocytic sarcoma, and chloroma in *Surgical Pathology, 11th Edition* published in 2018 \[[@CR9]\]. MS is not even listed In *WHO Classification of Tumours of the Digestive System, 4th Edition* \[[@CR10]\]. Hence, it appears desirable that, in the future, the definition of MS be unified regarding terminology.

In most cases of intestinal MS, patients exhibit symptoms of bowel obstruction. A review of the English-language literature between 2002 and 2019 revealed 18 cases of nonleukemic MS of the small intestine (Table [1](#Tab1){ref-type="table"}). Although the type of treatment was not described in 2 cases, the remaining 16 patients underwent surgical resection. Among these 18 patients, 12 were treated with chemotherapy for AML, all of whom experienced complete remission. Among the remaining 6 patients, 4 were treated with surgery only, and 2 of the 4 developed AML. It is important for patients with MS to have an early, accurate diagnosis and to start treatment for AML as soon as possible. Table 1Nonleukemic MS in the small intestine: summary of studies in the English-language literatureStudyAge/sexChief complaintNo. of tumorsFirst diagnosisTreatment modalityOutcomeWang et al. \[[@CR11]\]25/MAbdominal distension4MSSurgeryDeveloped AML after 3 monthsCicilet et al. \[[@CR12]\]45/FAbdominal pain and vomiting1MSNot describedNot describedHotta and Kunieda \[[@CR13]\]56/MVomiting1GSSurgery and chemotherapy for AML54 months, alive without recurrenceMcKenna et al. \[[@CR14]\]49/FAbdominal pain1MSSurgery and chemotherapy for AML2 years, alive without recurrencePalanivelu et al. \[[@CR15]\]52/MAbdominal distension and pain1GSSurgery14 months, alive without recurrenceKumar et al. \[[@CR16]\]55/FAbdominal pain and vomiting1GSSurgery and chemotherapy for AMLNot describedYoldaş et al. \[[@CR17]\]44/MAbdominal pain, distension, nausea, and vomiting1MSSurgery and chemotherapy9 postoperative months, alive without recurrenceKwan et al. \[[@CR18]\]39/FNausea, vomiting, diarrhea, abdominal pain1Crohn\'s diseaseSurgery, steroid therapy, and chemotherapy for AML2 years, alive without recurrenceWong et al. \[[@CR19]\]36/MAbdominal pain1GSSurgery and chemotherapy for AML1 postoperative year, alive without recurrenceIoannidis et al. \[[@CR20]\]48/MEpigastric pain, distension, vomiting1MSSurgery and AML chemotherapy6 months, alive without recurrenceLim et al. \[[@CR21]\]55/MAbdominal fullness and dyspepsia2MSNot describedNot describedLee et al. \[[@CR22]\]45/MAbdominal pain8GSSurgery and chemotherapy for AML12 months, alive without recurrenceKitagawa et al. \[[@CR2]\]33/FAbdominal pain and vomiting2GSSurgery and chemotherapy for AML and BMT57 months, alive without recurrenceMrad et al. \[[@CR23]\]13/FAbdominal mass2MSSurgery and chemotherapy for AML27 months, alive without recurrenceMcCusker et al. \[[@CR24]\]22/FAbdominal pain2Large-cell lymphomaSurgery, CHOP therapy, and chemotherapy for AML and BMT13 months, alive without recurrenceKim et al. \[[@CR25]\]49/MAbdominal pain5MSSurgeryDiedGajendra et al. \[[@CR26]\]35/MAbdominal pain3T-cell lymphomaSurgeryDeveloping AML after 1 monthJung et al. \[[@CR27]\]48/MAbdominal discomfortNot countableGSSurgery, chemotherapy for AML and BMT6 Months, alive without recurrence*AML* acute myeloid leukemia, *BMT* bone marrow transplantation, *CHOP* cyclophosphamide/hydroxydaunomycin/Oncovin/prednisone, *GS* granulomatous sarcoma, *MS* myeloid sarcoma

Conclusion {#Sec4}
==========

We report the case of an isolated MS that presented with small bowel obstruction. MS is not well known, and many patients with the disease have been assigned an incorrect diagnosis at their first evaluation. Although it is difficult to confirm the diagnosis---especially when MS precedes the occurrence of AML---it is imperative for MS patients to have an early, definitive diagnosis and to start treatment for AML as rapidly as possible. Therefore, we must cite MS as one of the differential diagnoses of small bowel tumors, even in patients without any symptoms of leukemia.
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